Literature DB >> 12540015

Shedding light on vascular permeability during peritonitis: role of mast cell histamine versus macrophage cysteinyl leukotrienes.

E Kolaczkowska1.   

Abstract

The inflammatory response consists of sequential steps that are essentially the same whatever the cause and wherever the site. The main purpose of inflammation is to bring fluid, proteins, and cells from the blood into the damaged tissues. Therefore there are mechanisms that allow cells and proteins to gain access to extravascular sites, where and when they are needed if damage and infection has occurred. A critical process for formation of inflammatory exudate is an increase in permeability of local blood vessels. Vasopermeability changes can be usually attributed to mast cells and their mediators but recent studies reveal that also macrophages can be involved in this process. This short commentary discusses new data on cellular origin of major vasoactive mediators, and their receptors during peritoneal inflammation in mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12540015     DOI: 10.1007/pl00012422

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  3 in total

Review 1.  Specialized pro-resolving lipid mediators in the inflammatory response: An update.

Authors:  Gerard Bannenberg; Charles N Serhan
Journal:  Biochim Biophys Acta       Date:  2010-08-10

2.  Ouabain Modulates Zymosan-Induced Peritonitis in Mice.

Authors:  Jacqueline Alves Leite; Anne Kaliery De Abreu Alves; José Guilherme Marques Galvão; Mariana Pires Teixeira; Luiz Henrique Agra Cavalcante-Silva; Cristoforo Scavone; Alexandre Morrot; Vivian Mary Rumjanek; Sandra Rodrigues-Mascarenhas
Journal:  Mediators Inflamm       Date:  2015-05-11       Impact factor: 4.711

3.  Effective activation of antioxidant system by immune-relevant factors reversely correlates with apoptosis of Eisenia andrei coelomocytes.

Authors:  J Homa; M Stalmach; G Wilczek; E Kolaczkowska
Journal:  J Comp Physiol B       Date:  2016-02-27       Impact factor: 2.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.